RU2012149618A - Менингококковые полипептиды fhbp - Google Patents
Менингококковые полипептиды fhbp Download PDFInfo
- Publication number
- RU2012149618A RU2012149618A RU2012149618/10A RU2012149618A RU2012149618A RU 2012149618 A RU2012149618 A RU 2012149618A RU 2012149618/10 A RU2012149618/10 A RU 2012149618/10A RU 2012149618 A RU2012149618 A RU 2012149618A RU 2012149618 A RU2012149618 A RU 2012149618A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- sequence
- polypeptide
- polypeptide according
- amino acid
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title claims abstract 27
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 27
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 10
- 239000012634 fragment Substances 0.000 claims abstract 8
- 150000001413 amino acids Chemical class 0.000 claims abstract 4
- 239000013612 plasmid Substances 0.000 claims abstract 4
- 230000002163 immunogen Effects 0.000 claims abstract 3
- 241000894006 Bacteria Species 0.000 claims abstract 2
- 239000012528 membrane Substances 0.000 claims abstract 2
- 102000039446 nucleic acids Human genes 0.000 claims abstract 2
- 108020004707 nucleic acids Proteins 0.000 claims abstract 2
- 150000007523 nucleic acids Chemical class 0.000 claims abstract 2
- 239000002773 nucleotide Substances 0.000 claims abstract 2
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 2
- 241000124008 Mammalia Species 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 230000008348 humoral response Effects 0.000 claims 2
- 241001174901 Neisseria meningitidis alpha275 Species 0.000 claims 1
- 241000921898 Neisseria meningitidis serogroup A Species 0.000 claims 1
- 241000947238 Neisseria meningitidis serogroup C Species 0.000 claims 1
- 241001573069 Neisseria meningitidis serogroup Y Species 0.000 claims 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Полипептид, содержащий аминокислотную последовательность, выбранную из группы, состоящей из последовательностей SEQ ID NO: 20, 23, 76, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 21, 22, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74 и 75.2. Полипептид по п.1, содержащий аминокислотную последовательность SEQ ID NO: 20.3. Полипептид по п.2, содержащий последовательность SEQ ID NO: 79.4. Полипептид по п.1, содержащий аминокислотную последовательность SEQ ID NO: 23.5. Полипептид по п.4, содержащий последовательность SEQ ID NO: 80.6. Полипептид по п.1, содержащий аминокислотную последовательность SEQ ID NO: 76.7. Полипептид по п.6, содержащий последовательность SEQ ID NO: 77.8. Полипептид, содержащий аминокислотную последовательность (i) которая имеет по меньшей мере 90% идентичность с последовательностью SEQ ID NO: 76 и/или (ii) содержит первый фрагмент и второй фрагмент последовательности SEQ ID NO: 76, где указанный первый фрагмент включает эпитоп, находящийся в пределах аминокислот 89-154 последовательности SEQ ID NO: 76, и указанный второй фрагмент включает эпитоп, находящийся в пределах аминокислот 187-248 последовательности SEQ ID NO: 76.9. Нуклеиновая кислота, кодирующая полипептид по любому из предшествующих пунктов.10. Плазмида, содержащая нуклеотидную последовательность, кодирующую полипептид по любому из пп.1-8.11. Клетка-хозяин, трансформированная плазмидой по п.10.12. Клетка-хозяин по п.11, где клетка является менингококковой бактерией.13. Мембранные везикулы, полученные из клетки-хозяина по п.12, где везикулы включают полипептид по любому из пп.1-8.14. Иммуногенная композиция, содержащая полипептид по любому из пп.1-8 или везикулу по п.13.15. Компо�
Claims (20)
1. Полипептид, содержащий аминокислотную последовательность, выбранную из группы, состоящей из последовательностей SEQ ID NO: 20, 23, 76, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 21, 22, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74 и 75.
2. Полипептид по п.1, содержащий аминокислотную последовательность SEQ ID NO: 20.
3. Полипептид по п.2, содержащий последовательность SEQ ID NO: 79.
4. Полипептид по п.1, содержащий аминокислотную последовательность SEQ ID NO: 23.
5. Полипептид по п.4, содержащий последовательность SEQ ID NO: 80.
6. Полипептид по п.1, содержащий аминокислотную последовательность SEQ ID NO: 76.
7. Полипептид по п.6, содержащий последовательность SEQ ID NO: 77.
8. Полипептид, содержащий аминокислотную последовательность (i) которая имеет по меньшей мере 90% идентичность с последовательностью SEQ ID NO: 76 и/или (ii) содержит первый фрагмент и второй фрагмент последовательности SEQ ID NO: 76, где указанный первый фрагмент включает эпитоп, находящийся в пределах аминокислот 89-154 последовательности SEQ ID NO: 76, и указанный второй фрагмент включает эпитоп, находящийся в пределах аминокислот 187-248 последовательности SEQ ID NO: 76.
9. Нуклеиновая кислота, кодирующая полипептид по любому из предшествующих пунктов.
10. Плазмида, содержащая нуклеотидную последовательность, кодирующую полипептид по любому из пп.1-8.
11. Клетка-хозяин, трансформированная плазмидой по п.10.
12. Клетка-хозяин по п.11, где клетка является менингококковой бактерией.
13. Мембранные везикулы, полученные из клетки-хозяина по п.12, где везикулы включают полипептид по любому из пп.1-8.
14. Иммуногенная композиция, содержащая полипептид по любому из пп.1-8 или везикулу по п.13.
15. Композиция по п.14, включающая адъювант.
16. Композиция по п.15, в которой адъювант содержит соль алюминия.
17. Композиция по любому из пп.14-16, дополнительно содержащая второй полипептид, который при введении млекопитающему вызывает гуморальный ответ в виде антител, которые являются бактерицидными против менингококка, при условии, что второй полипептид не является менингококковым fHBP.
18. Композиция по любому из пп.14-16, дополнительно содержащая конъюгированный капсулярный сахарид N. meningitidis серогруппы A, C, W135 и/или Y.
19. Композиция по любому из пп.14-16, дополнительно содержащая конъюгированный пневмококковый капсулярный сахарид.
20. Способ индуцирования гуморального ответа у млекопитающего, включающий введение иммуногенной композиции по любому из пп.14-19.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6671108P | 2008-02-21 | 2008-02-21 | |
| US61/066,711 | 2008-02-21 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010138815/10A Division RU2475496C2 (ru) | 2008-02-21 | 2009-02-20 | МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2012149618A true RU2012149618A (ru) | 2014-05-27 |
| RU2567003C2 RU2567003C2 (ru) | 2015-10-27 |
Family
ID=40775198
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010138815/10A RU2475496C2 (ru) | 2008-02-21 | 2009-02-20 | МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP |
| RU2012149618/10A RU2567003C2 (ru) | 2008-02-21 | 2012-11-21 | МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP |
| RU2015139827A RU2015139827A (ru) | 2008-02-21 | 2015-09-18 | МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010138815/10A RU2475496C2 (ru) | 2008-02-21 | 2009-02-20 | МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015139827A RU2015139827A (ru) | 2008-02-21 | 2015-09-18 | МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9579372B2 (ru) |
| EP (3) | EP2886551A3 (ru) |
| CN (1) | CN102356089B (ru) |
| AU (1) | AU2009215364B2 (ru) |
| BR (1) | BRPI0907843A2 (ru) |
| CA (1) | CA2716212A1 (ru) |
| ES (1) | ES2532946T3 (ru) |
| NZ (2) | NZ596805A (ru) |
| RU (3) | RU2475496C2 (ru) |
| WO (1) | WO2009104097A2 (ru) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2261345A3 (en) | 1998-05-01 | 2012-01-11 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
| PT2270173E (pt) | 1999-05-19 | 2016-03-28 | Glaxosmithkline Biologicals Sa | Composições de neisseria de combinação |
| PT2275552E (pt) | 1999-10-29 | 2015-12-07 | Glaxosmithkline Biolog Sa | Péptidos antigénicos de neisseria |
| EP1261723B1 (en) | 2000-02-28 | 2008-02-27 | Novartis Vaccines and Diagnostics S.r.l. | Hybrid expression of neisserial proteins |
| GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| HUE047780T2 (hu) | 2002-10-11 | 2020-05-28 | Glaxosmithkline Biologicals Sa | Polipeptid vakcinák hipervirulens meningokokkusz vonalak elleni széles-spektrumú védelemre |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| BRPI0907843A2 (pt) | 2008-02-21 | 2015-08-04 | Novartis Ag | Polipeptídeos de fhbp menigocócicos |
| CN104548082A (zh) | 2009-03-24 | 2015-04-29 | 诺华股份有限公司 | 为脑膜炎球菌因子h结合蛋白添加佐剂 |
| JP2013502918A (ja) | 2009-08-27 | 2013-01-31 | ノバルティス アーゲー | 髄膜炎菌ｆＨＢＰ配列を含むハイブリッドポリペプチド |
| JP2013503148A (ja) | 2009-08-27 | 2013-01-31 | ノバルティス アーゲー | アルミニウム、オリゴヌクレオチドおよびポリカチオンを含むアジュバント |
| WO2011039631A2 (en) | 2009-09-30 | 2011-04-07 | Novartis Ag | Expression of meningococcal fhbp polypeptides |
| US20130022633A1 (en) * | 2009-10-27 | 2013-01-24 | University Of Florence | MENINGOCOCCAL fHBP POLYPEPTIDES |
| MX2012010609A (es) * | 2010-03-18 | 2012-10-03 | Novartis Ag | Vacunas adyuvadas para meningococos serogrupo b. |
| EP2552942B1 (en) * | 2010-03-30 | 2017-12-27 | Children's Hospital & Research Center at Oakland | Factor h binding proteins (fhbp) with altered properties and methods of use thereof |
| CA2803239A1 (en) | 2010-06-25 | 2011-12-29 | Novartis Ag | Combinations of meningococcal factor h binding proteins |
| EP3246044B2 (en) | 2010-08-23 | 2024-04-10 | Wyeth LLC | Stable formulations of neisseria meningitidis rlp2086 antigens |
| ES2864635T3 (es) | 2010-09-10 | 2021-10-14 | Wyeth Llc | Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis |
| ES2759484T3 (es) | 2010-09-10 | 2020-05-11 | Glaxosmithkline Biologicals Sa | Meningococo que sobreexpresa NadA y/o NHBA y vesículas de la membrana externa derivadas del mismo |
| EP2707009A1 (en) | 2011-05-12 | 2014-03-19 | Novartis AG | Antipyretics to enhance tolerability of vesicle-based vaccines |
| BR112014016223A8 (pt) | 2011-12-29 | 2017-07-04 | Novartis Ag | combinações adjuvantes de proteínas de ligação de fator h meningocócico |
| AU2013214105A1 (en) | 2012-02-02 | 2014-07-24 | Novartis Ag | Promoters for increased protein expression in meningococcus |
| US10598666B2 (en) | 2012-03-08 | 2020-03-24 | Glaxosmithkline Biologicals Sa | In vitro potency assay for protein-based meningococcal vaccines |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| WO2013132452A2 (en) * | 2012-03-09 | 2013-09-12 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| EP2833911A4 (en) | 2012-04-06 | 2016-07-13 | Univ Cornell | SUB-VACCINE VACCINATING PLATFORM FOR ROBUST HUMORAL AND CELLULAR IMMUNE RESPONSES |
| US9427476B2 (en) | 2012-05-24 | 2016-08-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Multivalent meningococcal conjugates and methods for preparing conjugates |
| EP2861247B1 (en) | 2012-06-14 | 2020-12-09 | GlaxoSmithKline Biologicals SA | Vaccines for serogroup x meningococcus |
| EP2877492A1 (en) | 2012-07-27 | 2015-06-03 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia |
| RU2015106930A (ru) | 2012-09-06 | 2016-10-20 | Новартис Аг | Комбинированные вакцины с менингококком серогруппы в и к/д/с |
| JP6446377B2 (ja) | 2013-03-08 | 2018-12-26 | ファイザー・インク | 免疫原性融合ポリペプチド |
| BR112016002150A2 (pt) | 2013-08-02 | 2017-09-12 | Children´S Hospital & Res Center At Oakland | proteínas de ligação de fator h de ocorrência natural (fhbp) e métodos de uso das mesmas |
| KR20210002757A (ko) | 2013-09-08 | 2021-01-08 | 화이자 인코포레이티드 | 나이세리아 메닌지티디스 조성물 및 그의 방법 |
| KR102779223B1 (ko) | 2014-02-28 | 2025-03-07 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 변형된 수막구균 fhbp 폴리펩티드 |
| CA2955802C (en) | 2014-07-23 | 2023-10-31 | Children's Hospital & Research Center At Oakland | Factor h binding protein variants and methods of use thereof |
| AU2016221318B2 (en) * | 2015-02-19 | 2020-06-25 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| GB201614687D0 (en) * | 2016-08-31 | 2016-10-12 | Univ Oxford Innovation Ltd | fHbp scaffold |
| US12109259B2 (en) | 2016-09-02 | 2024-10-08 | Glaxosmithkline Biologicals Sa | Vaccines for Neisseria gonorrhoeae |
| EP3312192B1 (en) * | 2016-10-24 | 2023-02-22 | BiOMVis Srl | Immunogenic compositions containing bacterial outer membrane vesicles |
| PE20191107A1 (es) | 2017-01-31 | 2019-08-26 | Pfizer | Composiciones de neisseria meningitidis y metodos respectivos |
| CN109485704B (zh) * | 2018-11-27 | 2022-04-19 | 温州大学 | 一种脑膜炎球菌fHbp蛋白的表达系统 |
| BR112022004921A2 (pt) | 2019-09-27 | 2022-07-19 | Pfizer | Composições para neisseria meningitidis e métodos das mesmas |
Family Cites Families (144)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4057685A (en) | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
| DE2848965A1 (de) | 1978-11-11 | 1980-05-22 | Behringwerke Ag | Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine |
| AU545912B2 (en) | 1980-03-10 | 1985-08-08 | Cetus Corporation | Cloned heterologous jive products in bacillies |
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| DK188582A (da) | 1981-04-29 | 1982-10-30 | Biogen Nv | Bacillus-kloningsvektorer rekombinations-dna-molekyler bacillus-vaerter transformeret dermed samt fremgangsmaader til ekspressionaf fremmede dna-sekvenser og fremstilling af polypeptideer som er kodede dermed |
| US4551433A (en) | 1981-05-18 | 1985-11-05 | Genentech, Inc. | Microbial hybrid promoters |
| US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
| JPS59166086A (ja) | 1983-03-09 | 1984-09-19 | Teruhiko Beppu | 新規な発現型プラスミドとそれらを用いて仔牛プロキモシン遺伝子を大腸菌内で発現させる方法 |
| US4663160A (en) | 1983-03-14 | 1987-05-05 | Miles Laboratories, Inc. | Vaccines for gram-negative bacteria |
| JPS59205983A (ja) | 1983-04-28 | 1984-11-21 | ジエネツクス・コ−ポレイシヨン | 異種遺伝子を原核微生物で発現させる方法 |
| US4663280A (en) | 1983-05-19 | 1987-05-05 | Public Health Research Institute Of The City Of New York | Expression and secretion vectors and method of constructing vectors |
| US4761283A (en) | 1983-07-05 | 1988-08-02 | The University Of Rochester | Immunogenic conjugates |
| US4689406A (en) | 1983-08-10 | 1987-08-25 | Amgen | Enhancement of microbial expression of polypeptides |
| JPS6054685A (ja) | 1983-09-02 | 1985-03-29 | Suntory Ltd | 改良発現ベクタ−およびその利用 |
| EP0136907A3 (en) | 1983-10-03 | 1986-12-30 | Genentech, Inc. | A xenogeneic expression control system, a method of using it, expression vectors containing it, cells transformed thereby and heterologous proteins produced therefrom |
| US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
| US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
| US4882317A (en) | 1984-05-10 | 1989-11-21 | Merck & Co., Inc. | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency |
| US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
| US4808700A (en) | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
| US4738921A (en) | 1984-09-27 | 1988-04-19 | Eli Lilly And Company | Derivative of the tryptophan operon for expression of fused gene products |
| US4745056A (en) | 1984-10-23 | 1988-05-17 | Biotechnica International, Inc. | Streptomyces secretion vector |
| IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
| US4865974A (en) | 1985-09-20 | 1989-09-12 | Cetus Corporation | Bacterial methionine N-terminal peptidase |
| JPS63123383A (ja) | 1986-11-11 | 1988-05-27 | Mitsubishi Kasei Corp | ハイブリツドプロモ−タ−、発現調節ｄｎａ配列および発現ベクタ− |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| JPH01125328A (ja) | 1987-07-30 | 1989-05-17 | Centro Natl De Biopreparados | 髄膜炎菌ワクチン |
| NL8802046A (nl) | 1988-08-18 | 1990-03-16 | Gen Electric | Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen. |
| JPH04500203A (ja) | 1988-08-25 | 1992-01-16 | ザ リポソーム カンパニー，インコーポレイテッド | インフルエンザワクチンおよび新規なアジュバント |
| DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
| AU640118B2 (en) | 1988-12-19 | 1993-08-19 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur | Meningococcal class 1 outer-membrane protein vaccine |
| ES2055785T3 (es) | 1989-01-17 | 1994-09-01 | Eniricerche Spa | Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas. |
| JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
| EP0482068A1 (en) | 1989-07-14 | 1992-04-29 | American Cyanamid Company | Cytokine and hormone carriers for conjugate vaccines |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| EP0467714A1 (en) | 1990-07-19 | 1992-01-22 | Merck & Co. Inc. | The class II protein of the outer membrane of neisseria meningitidis |
| IL98715A0 (en) | 1990-08-13 | 1992-07-15 | American Cyanamid Co | Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| ATE188613T1 (de) | 1992-06-25 | 2000-01-15 | Smithkline Beecham Biolog | Adjuvantien enthaltende impfstoffzusammensetzung |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| NL9201716A (nl) | 1992-10-02 | 1994-05-02 | Nederlanden Staat | Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat. |
| JP4028593B2 (ja) | 1993-03-23 | 2007-12-26 | グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム | ３−ｏ脱アシル化モノホスホリルリピドａ含有ワクチン組成物 |
| KR100376361B1 (ko) | 1993-09-22 | 2003-07-18 | 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신 | 면역원성구조체의제조를위하여신규한시아닐레이팅시약을사용하여용해성탄수화물을활성화하는방법 |
| GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
| UA56132C2 (ru) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиция вакцины (варианты), способ стабилизации qs21 по отношению к гидролизу (варианты), способ приготовления вакцины |
| US6180111B1 (en) | 1995-05-18 | 2001-01-30 | University Of Maryland | Vaccine delivery system |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| US6558677B2 (en) | 1996-10-15 | 2003-05-06 | Wendell D. Zollinger | Vaccine against gram negative bacteria |
| AU5426098A (en) | 1996-10-24 | 1998-05-15 | Emory University | Invasion associated genes from (neisseria meningitidis) serogroup |
| JP2001501833A (ja) | 1996-10-31 | 2001-02-13 | ヒューマン ジノーム サイエンシーズ，インコーポレイテッド | Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅのポリヌクレオチドおよび配列 |
| EP1005368B1 (en) | 1997-03-10 | 2009-09-02 | Ottawa Hospital Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants |
| US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
| GB9711964D0 (en) | 1997-06-09 | 1997-08-06 | Medical Res Council | Live attenuated vaccines |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| ES2301181T3 (es) | 1997-08-21 | 2008-06-16 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Mutantes nuevos de bacterias mucosas gram negativas y su aplicacion en vacunas. |
| DE69838992T2 (de) | 1997-09-05 | 2008-12-24 | Glaxosmithkline Biologicals S.A., Rixensart | Öl-in-Wasser Emulsionen mit Saponinen |
| US6914131B1 (en) | 1998-10-09 | 2005-07-05 | Chiron S.R.L. | Neisserial antigens |
| CA2308606A1 (en) | 1997-11-06 | 1999-05-20 | Chiron S.P.A. | Neisserial antigens |
| GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| ATE446368T1 (de) | 1998-01-14 | 2009-11-15 | Novartis Vaccines & Diagnostic | Antigene aus neisseria meningitidis |
| CN1200730C (zh) | 1998-02-12 | 2005-05-11 | 惠氏控股有限公司 | 用白细胞介素－12配制的肺炎球菌和脑膜炎球菌疫苗 |
| US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
| CA2325939A1 (en) | 1998-04-09 | 1999-10-21 | Martin Friede | Vaccine |
| US20070026021A1 (en) | 1998-05-01 | 2007-02-01 | Chiron S.R.I. | Neisseria meningitidis antigens and compositions |
| EP2261345A3 (en) | 1998-05-01 | 2012-01-11 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
| US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
| GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| HK1041825B (zh) | 1998-08-19 | 2007-02-23 | Baxter Healthcare S.A. | 多糖-蛋白质缀合物或寡糖-蛋白质缀合物、其制备方法及其应用 |
| JP2004511201A (ja) | 1998-10-09 | 2004-04-15 | カイロン コーポレイション | ナイセリアゲノム配列およびそれらの使用方法 |
| EP1588714A2 (en) | 1998-10-16 | 2005-10-26 | GlaxoSmithKline Biologicals S.A. | Adjuvant systems and vaccines |
| GB9823978D0 (en) | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
| WO2000033882A1 (en) | 1998-12-04 | 2000-06-15 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | A vi-repa conjugate vaccine for immunization against salmonella typhi |
| BR0009166A (pt) | 1999-03-19 | 2001-12-26 | Smithkline Beecham Biolog | Vacina |
| WO2000061761A2 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| JP2003527079A (ja) | 1999-04-30 | 2003-09-16 | カイロン コーポレイション | ナイセリアゲノム配列およびそれらの使用方法 |
| PT2270173E (pt) | 1999-05-19 | 2016-03-28 | Glaxosmithkline Biologicals Sa | Composições de neisseria de combinação |
| GB9918319D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
| KR20020038770A (ko) | 1999-09-24 | 2002-05-23 | 장 스테판느 | 애쥬번트로서의 폴리옥시에틸렌 소르비탄 에스테르와옥톡시놀의 조합물의 용도 및 백신과 관련된 이의 용도 |
| JP2003509452A (ja) | 1999-09-24 | 2003-03-11 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ポリオキシエチレンアルキルエーテル又はエステル及び少なくとも一つのノニオン界面活性剤を含有するアジュバント |
| GB9925559D0 (en) | 1999-10-28 | 1999-12-29 | Smithkline Beecham Biolog | Novel method |
| PT2275552E (pt) | 1999-10-29 | 2015-12-07 | Glaxosmithkline Biolog Sa | Péptidos antigénicos de neisseria |
| AU1917501A (en) | 1999-11-12 | 2001-06-06 | University Of Iowa Research Foundation, The | Control of neisserial membrane synthesis |
| ES2588917T3 (es) | 2000-01-17 | 2016-11-07 | Glaxosmithkline Biologicals Sa | Vacuna de VME suplementada contra meningococo |
| EP1311288A1 (en) | 2000-01-20 | 2003-05-21 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
| EP1261723B1 (en) | 2000-02-28 | 2008-02-27 | Novartis Vaccines and Diagnostics S.r.l. | Hybrid expression of neisserial proteins |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| NO20002828D0 (no) | 2000-06-02 | 2000-06-02 | Statens Inst For Folkehelse | Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav |
| WO2002009643A2 (en) | 2000-07-27 | 2002-02-07 | Children's Hospital & Research Center At Oakland | Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
| GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| ES2298269T3 (es) | 2000-09-26 | 2008-05-16 | Idera Pharmaceuticals, Inc. | Modulacion de la actividad inmunoestimulante de analogos oligonucleotidicos inmunoestimulantes mediante cambios quimicos posicionales. |
| MXPA03003690A (es) | 2000-10-27 | 2004-05-05 | Chiron Spa | Acidos nucleicos y proteinas de los grupos a y b de estreptococos. |
| GB0103169D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| GB0103171D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| US20030035806A1 (en) | 2001-05-11 | 2003-02-20 | D'ambra Anello J. | Novel meningitis conjugate vaccine |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| EP1409013B1 (en) | 2001-07-26 | 2009-11-18 | Novartis Vaccines and Diagnostics S.r.l. | Vaccines comprising aluminium adjuvants and histidine |
| GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| AU2002339224B2 (en) | 2001-09-14 | 2008-10-09 | Kuros Us Llc | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
| EP1425040A2 (en) | 2001-09-14 | 2004-06-09 | Cytos Biotechnology AG | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| MX339524B (es) * | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| GB0130123D0 (en) | 2001-12-17 | 2002-02-06 | Microbiological Res Agency | Outer membrane vesicle vaccine and its preparation |
| US6792355B2 (en) | 2001-12-21 | 2004-09-14 | Triad Therapeutics, Inc. | Methods for determining polypeptide structure, function or pharmacophore from comparison of polypeptide sequences |
| DK1777236T3 (en) | 2002-03-26 | 2017-02-27 | Glaxosmithkline Biologicals Sa | MODIFIED SUCCARIDES WHICH IMPROVED WATER STABILITY FOR USE AS A MEDICINE |
| ES2537737T3 (es) | 2002-08-02 | 2015-06-11 | Glaxosmithkline Biologicals S.A. | Composiciones de vacuna que comprenden lipooligosacáridos de inmunotipo L2 y/o L3 de Neisseria meningitidis de IgtB |
| GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| US7785608B2 (en) * | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
| HUE047780T2 (hu) | 2002-10-11 | 2020-05-28 | Glaxosmithkline Biologicals Sa | Polipeptid vakcinák hipervirulens meningokokkusz vonalak elleni széles-spektrumú védelemre |
| WO2004046177A2 (en) | 2002-11-15 | 2004-06-03 | Chiron Srl | Unexpected surface proteins in neisseria meningitidis |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| US20070148729A1 (en) | 2003-01-15 | 2007-06-28 | Farley John E | Methods for increasing neisseria protein expression and compositions thereof |
| CN101926988B (zh) * | 2003-01-30 | 2014-06-04 | 诺华疫苗和诊断有限公司 | 抗多种脑膜炎球菌血清组的可注射性疫苗 |
| CN1867354A (zh) | 2003-04-16 | 2006-11-22 | 惠氏控股有限公司 | 预防和治疗脑膜炎球菌疾病的新颖免疫原性组合物 |
| GB0316560D0 (en) | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
| ATE506963T1 (de) | 2003-10-02 | 2011-05-15 | Novartis Vaccines & Diagnostic | Kombinationsimpfstoffe gegen meningitis |
| GB0419408D0 (en) | 2004-09-01 | 2004-10-06 | Chiron Srl | 741 chimeric polypeptides |
| ES2616294T3 (es) | 2005-01-27 | 2017-06-12 | Children's Hospital & Research Center At Oakland | Vacunas de vesículas basadas en GNA1870 para protección de amplio espectro contra enfermedades provocadas por Neisseria meningitidis |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
| AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
| WO2008125985A2 (en) | 2007-04-11 | 2008-10-23 | Novartis Ag | Blocking interaction between pathogen factors and factor h to inhibit hemorrhagic syndromes |
| CA2688268A1 (en) | 2007-06-04 | 2008-12-11 | Novartis Ag | Formulation of meningitis vaccines |
| WO2009038889A1 (en) | 2007-08-02 | 2009-03-26 | Children's Hospital And Research Center At Oakland | Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
| BRPI0907843A2 (pt) | 2008-02-21 | 2015-08-04 | Novartis Ag | Polipeptídeos de fhbp menigocócicos |
| WO2009114485A2 (en) * | 2008-03-10 | 2009-09-17 | Children's Hospital & Research Center At Oakland | Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use |
| WO2010028096A2 (en) | 2008-09-03 | 2010-03-11 | Children's Hospital & Research Center At Oakland | Peptides presenting an epitope of an a domain of factor h binding protein and methods of use |
| IT1394288B1 (it) | 2008-09-12 | 2012-06-06 | Novartis Vaccines & Diagnostic | Immunogeni di proteine che legano il fattore h. |
| GB0819633D0 (en) | 2008-10-25 | 2008-12-03 | Isis Innovation | Composition |
| CN104548082A (zh) | 2009-03-24 | 2015-04-29 | 诺华股份有限公司 | 为脑膜炎球菌因子h结合蛋白添加佐剂 |
| EP2282263A1 (fr) | 2009-07-31 | 2011-02-09 | Gemalto SA | Procédé de configuration fonctionnelle d'un circuit intégré pour carte à puce en vue d'une utilisation optimale de ses ressources |
| CA2792683A1 (en) | 2010-03-10 | 2011-09-15 | Glaxosmithkline Biologicals S.A. | Neisserial fhbp vaccine composition |
| US9427476B2 (en) | 2012-05-24 | 2016-08-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Multivalent meningococcal conjugates and methods for preparing conjugates |
-
2009
- 2009-02-20 BR BRPI0907843-6A patent/BRPI0907843A2/pt not_active IP Right Cessation
- 2009-02-20 EP EP14200294.8A patent/EP2886551A3/en not_active Withdrawn
- 2009-02-20 NZ NZ596805A patent/NZ596805A/xx not_active IP Right Cessation
- 2009-02-20 ES ES09713537.0T patent/ES2532946T3/es active Active
- 2009-02-20 CA CA2716212A patent/CA2716212A1/en not_active Abandoned
- 2009-02-20 US US12/918,729 patent/US9579372B2/en active Active
- 2009-02-20 AU AU2009215364A patent/AU2009215364B2/en not_active Ceased
- 2009-02-20 RU RU2010138815/10A patent/RU2475496C2/ru not_active IP Right Cessation
- 2009-02-20 WO PCT/IB2009/005038 patent/WO2009104097A2/en not_active Ceased
- 2009-02-20 CN CN200980110581.1A patent/CN102356089B/zh not_active Expired - Fee Related
- 2009-02-20 NZ NZ587382A patent/NZ587382A/en not_active IP Right Cessation
- 2009-02-20 EP EP09713537.0A patent/EP2245048B1/en not_active Not-in-force
- 2009-02-20 EP EP17184493.9A patent/EP3263591B1/en active Active
-
2012
- 2012-11-21 RU RU2012149618/10A patent/RU2567003C2/ru not_active IP Right Cessation
-
2013
- 2013-01-08 US US13/736,850 patent/US9468673B2/en active Active
-
2015
- 2015-09-18 RU RU2015139827A patent/RU2015139827A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP3263591B1 (en) | 2019-03-27 |
| CN102356089A (zh) | 2012-02-15 |
| NZ596805A (en) | 2013-06-28 |
| RU2475496C2 (ru) | 2013-02-20 |
| US20110020390A1 (en) | 2011-01-27 |
| WO2009104097A2 (en) | 2009-08-27 |
| CN102356089B (zh) | 2014-02-19 |
| US9579372B2 (en) | 2017-02-28 |
| AU2009215364B2 (en) | 2014-09-18 |
| EP2245048A2 (en) | 2010-11-03 |
| EP2245048B1 (en) | 2014-12-31 |
| RU2567003C2 (ru) | 2015-10-27 |
| RU2015139827A (ru) | 2017-03-23 |
| US9468673B2 (en) | 2016-10-18 |
| WO2009104097A3 (en) | 2009-12-03 |
| ES2532946T3 (es) | 2015-04-06 |
| BRPI0907843A2 (pt) | 2015-08-04 |
| AU2009215364A1 (en) | 2009-08-27 |
| RU2010138815A (ru) | 2012-03-27 |
| NZ587382A (en) | 2012-01-12 |
| US20130115238A1 (en) | 2013-05-09 |
| EP2886551A2 (en) | 2015-06-24 |
| EP2886551A3 (en) | 2015-09-23 |
| EP3263591A1 (en) | 2018-01-03 |
| CA2716212A1 (en) | 2009-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012149618A (ru) | Менингококковые полипептиды fhbp | |
| JP2013502918A5 (ru) | ||
| ES2251124T3 (es) | Vacuna que comprende un antigeno de streptococcus pneumoniae adyuvado por un oligonucleotido cpg. | |
| CA2506318A1 (en) | Unexpected surface proteins in neisseria meningitidis | |
| RU2378009C2 (ru) | Иммунизация против менингококков серогруппы y с помощью белков | |
| EP2248535A1 (en) | Multicomponent meningococcal vaccine | |
| BE1022641B1 (fr) | POLYPEPTIDES MENINGOCOCCIQUES fHbp MODIFIES | |
| JP2013522287A5 (ru) | ||
| TR200400621T2 (tr) | GDF-8 aktivitesinin aşağı doğru düzenlenmesi için bir yöntem. | |
| RU2014122163A (ru) | Комбинации, включающие сахарид пневмококка серотипа 14 | |
| BR9914374A (pt) | Sequências genÈmicas de neisseria e métodos para seu uso | |
| BE1022878B1 (fr) | Vaccins anti-meningococciques | |
| JP2017114874A (ja) | 免疫原性組成物 | |
| JP2013176371A (ja) | 髄膜炎菌タンパク質ｎｍｂ１８７０の複数の改変体 | |
| JP2006500963A (ja) | ワクチン組成物 | |
| RU2010153658A (ru) | Мультивалентная вакцина из нативных везикул наружной мембраны менингококков, способы ее получения и применения | |
| JP2012521404A5 (ru) | ||
| ES2847923T3 (es) | Vacunas contra el meningococo del serogrupo X | |
| JP2017522319A5 (ru) | ||
| JP2015505309A5 (ru) | ||
| WO2008021296A3 (en) | Compositions and methods for the treatment and prophylaxis of alzheimer's disease | |
| JP2002534481A5 (ru) | ||
| CN104072590B (zh) | 一种脑膜炎球菌抗原组合及其应用 | |
| ES2351598T3 (es) | Proteína frpb mutante y procedimiento de replegamiento. | |
| US20060182768A1 (en) | Peptides and DNA encoding the peptides useful for immunizations against Coccidioides spp. infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20180221 |